AbbVie’s recently approved hepatitis C virus (HCV) regimen Mavyret (glecaprevir/pibrentasvir) is associated with stable or improved health-related quality of life (HRQL).
Researchers analyzed pooled results from the Phase III CERTAIN I and CERTAIN II trials of eight or 12 weeks of Mavyret treatment. (The respective trials had hep C cure rates of 99 percent and 100 percent.) Results were presented at the Annual Meeting of the American Association for the Study of Liver Diseases in Washington, DC.
The investigators looked at the results of the EuroQol five dimensions questionnaire (EQ-5D-3l), which tests HRQL. The tests were administered before treatment, at the end of treatment and 12 weeks posttreatment. The EQ-5D-31 has a low score of -0.11 and a top score of 1, which indicates ideal health.
A total of 229 people were treated for eight weeks and 103 were treated for 12 weeks.
Before treatment, 78.2 percent of the participants had a score of 1 on the EQ-5D-31, indicating perfect health. This proportion increased to 84.9 percent by the end of treatment and remained higher 12 weeks after that, at 81.5 percent. Those who had been treated for hep C before saw a steeper jump on this measure, from 67.9 percent to 78 percent to 80.8 percent at the three respective time points.
On average, those in the eight- and 12-week groups saw their EQ-5D-31 score on this test increase by a respective 0.0185 and 0.0254. This upward trend held true independent of whether participants had cirrhosis at the study’s outset, their age or their kidney function.
To read the conference abstract, click here.